The Global Viscosupplementation Market size is expected to reach $8.2 billion by 2030, rising at a market growth of 8.6% CAGR during the forecast period.
The North America region will capture around 30% share in the market by 2030. Due to factors like the increasing incidence of osteoarthritis and related disorders, the growing geriatric population, the well-developed healthcare infrastructure, and increasing demand for non-surgical procedures. The demand for viscosupplementation is increasing due to the rising prevalence of arthritis, osteoarthritis, and knee pain. Some of the factors impacting the market are increased demand for minimally invasive therapies, increasing elderly population with osteoarthritis, and increase in cardiovascular risk due to use of NSAIDs for osteoarthritis.
Less pain, fewer complications, and a shortened hospital stay are associated with minimally invasive surgery. Minimally invasive surgical techniques are used to perform procedures in the fields of cardiothoracic surgery, gastroesophageal reflux disease, gastroenterology, gynecological surgery, heart surgery, pediatric surgery, urogynecology and pelvic reconstructive surgery, and urological surgery. Minimally invasive procedures can be used for both diagnostic and therapeutic procedures. Furthermore, due to age-related changes in the body, such as impaired cartilage repair capacity and changes in joint structure, which contribute to the disease's development and progression, elderly persons are more prone to various health issues, including osteoarthritis. The incidence of OA is predicted to increase, putting a substantial burden on people, health systems, and social care systems around the world due to the rise in the geriatric population and the high prevalence of obesity. According to the Arthritis Foundation, osteoarthritis will affect 130 million people globally by 2050. Therefore, the rising demand for minimally invasive therapy and growth in the number of elderly populations with osteoarthritis will aid in increasing demand for viscosupplementation treatments, thereby driving market growth.
However, patients with osteoarthritis commonly use OTC and prescription NSAIDs to alleviate discomfort. According to a 2019 National Center for Biotechnology Information report, NSAIDs are administered to more than 50% of osteoarthritis patients in the US. In Europe, 60% of osteoarthritis patients receiving prescription medications (47%) were prescribed NSAIDs. The use of NSAIDs raises the risk of adverse cardiovascular events. Patients' CVD risk is increased by cyclooxygenase (COX)-2 selective NSAIDs (coxibs) and non-selective NSAIDs. Heart failure (HF), increased blood pressure, atrial fibrillation, and venous thromboembolism are further patient-important events. This factor poses a challenge for the market. Additionally, market expansion for viscosupplementation was adversely affected by the COVID-19 outbreak. Most procedures were canceled or delayed during the COVID-19 pandemic because viscosupplementation was a non-emergency procedure. It, therefore, reduced the demand for viscosupplementation and prevented market expansion. The market was also significantly impacted because most viscosupplementation product users are senior citizens. This group was generally advised to stay home to lower the risk of infection.
Application Outlook
By application, the market is divided into knee osteoarthritis, hand osteoarthritis, hip osteoarthritis, and others. The knee osteoarthritis segment acquired the maximum revenue share in the market in 2022. Because of recent improvements in life expectancy as well as body mass index (BMI), it is thought that knee osteoarthritis (OA) has become common nowadays. Strong evidence suggests that the breakdown of tissues in joints brought on by mechanical strain and inflammation is the primary cause of knee OA.
Product Outlook
By product, the market is categorized into single injection, three injection, and five injections. The single injection segment covered a considerable revenue share in the market in 2022. Over the projected period, the single-injection segment is anticipated to increase the fastest. These injections are relatively new on the market but are growing quickly due to their shorter regimen, fewer hospital visits, lack of side effects, and low discomfort.
End-use Outlook
Based on end-use, the market is bifurcated into hospitals and orthopedic clinics/ASCs. In 2022 the orthopedic clinics/ASCs segment witnessed the largest revenue share in the market. Due to ASCs' ability to do same-day procedures including ACL reconstruction, hip, knee, and shoulder replacements, among others, the clinics/ASCs segment is also predicted to expand at the quickest rate. These operations are less complex and require minimal hospitalization.
Regional Outlook
Region wise, the market is analyzed across into North America, Europe, Asia Pacific, and LAMEA. In 2022 the Asia Pacific region dominated the market by generating the highest revenue share. One of the key factors boosting the market in this region is the presence of elderly population prone to osteoarthritis. In addition, many individuals in the Asia Pacific region prefer non-surgical treatment options due to cultural beliefs, fear of surgery, and the desire to avoid post-operative complications. Viscosupplementation offers a minimally invasive alternative to surgical interventions like joint replacement.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include DePuy Synthes (Johnson & Johnson), Sanofi S.A., Zimmer Biomet Holdings, Inc., Ferring Holdings SA, F. Hoffmann-La Roche Ltd., LG Chem Ltd. (LG Corporation), Anika Therapeutics, Inc., Fidia Farmaceutici S.p.A. (P&R Farmaceutici S.p.A), Smith & Nephew PLC and Seikagaku Corp.
Scope of the Study
Market Segments covered in the Report:
By Application
- Knee Osteoarthritis
- Hand Osteoarthritis
- Hip Osteoarthritis
- Others
By Product
- Three Injection
- Single Injection
- Five Injection
By End-use
- Hospitals
- Orthopedic Clinics/ASCs
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- DePuy Synthes (Johnson & Johnson)
- Sanofi S.A.
- Zimmer Biomet Holdings, Inc.
- Ferring Holdings SA
- F. Hoffmann-La Roche Ltd.
- LG Chem Ltd. (LG Corporation)
- Anika Therapeutics, Inc.
- Fidia Farmaceutici S.p.A. (P&R Farmaceutici S.p.A)
- Smith & Nephew PLC
- Seikagaku Corp.
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 Global Viscosupplementation Market, by Application
- 1.4.2 Global Viscosupplementation Market, by Product
- 1.4.3 Global Viscosupplementation Market, by End-use
- 1.4.4 Global Viscosupplementation Market, by Geography
- 1.5 Methodology for the research
Chapter 2. Market At a Glance
Chapter 3. Market Overview
- 3.1 Introduction
- 3.1.1 Overview
- 3.1.1.1 Market Composition and Scenario
- 3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints
- 3.3 Porter's Five Force Analysis
Chapter 4. Global Viscosupplementation Market by Application
- 4.1 Global Knee Osteoarthritis Market by Region
- 4.2 Global Hand Osteoarthritis Market by Region
- 4.3 Global Hip Osteoarthritis Market by Region
- 4.4 Global Others Market by Region
Chapter 5. Global Viscosupplementation Market by Product
- 5.1 Global Three Injection Market by Region
- 5.2 Global Single Injection Market by Region
- 5.3 Global Five Injection Market by Region
Chapter 6. Global Viscosupplementation Market by End-use
- 6.1 Global Hospitals Market by Region
- 6.2 Global Orthopedic Clinics/ASCs Market by Region
Chapter 7. Global Viscosupplementation Market by Region
- 7.1 North America Viscosupplementation Market
- 7.1.1 North America Viscosupplementation Market by Application
- 7.1.1.1 North America Knee Osteoarthritis Market by Country
- 7.1.1.2 North America Hand Osteoarthritis Market by Country
- 7.1.1.3 North America Hip Osteoarthritis Market by Country
- 7.1.1.4 North America Others Market by Country
- 7.1.2 North America Viscosupplementation Market by Product
- 7.1.2.1 North America Three Injection Market by Country
- 7.1.2.2 North America Single Injection Market by Country
- 7.1.2.3 North America Five Injection Market by Country
- 7.1.3 North America Viscosupplementation Market by End-use
- 7.1.3.1 North America Hospitals Market by Country
- 7.1.3.2 North America Orthopedic Clinics/ASCs Market by Country
- 7.1.4 North America Viscosupplementation Market by Country
- 7.1.4.1 US Viscosupplementation Market
- 7.1.4.1.1 US Viscosupplementation Market by Application
- 7.1.4.1.2 US Viscosupplementation Market by Product
- 7.1.4.1.3 US Viscosupplementation Market by End-use
- 7.1.4.2 Canada Viscosupplementation Market
- 7.1.4.2.1 Canada Viscosupplementation Market by Application
- 7.1.4.2.2 Canada Viscosupplementation Market by Product
- 7.1.4.2.3 Canada Viscosupplementation Market by End-use
- 7.1.4.3 Mexico Viscosupplementation Market
- 7.1.4.3.1 Mexico Viscosupplementation Market by Application
- 7.1.4.3.2 Mexico Viscosupplementation Market by Product
- 7.1.4.3.3 Mexico Viscosupplementation Market by End-use
- 7.1.4.4 Rest of North America Viscosupplementation Market
- 7.1.4.4.1 Rest of North America Viscosupplementation Market by Application
- 7.1.4.4.2 Rest of North America Viscosupplementation Market by Product
- 7.1.4.4.3 Rest of North America Viscosupplementation Market by End-use
- 7.2 Europe Viscosupplementation Market
- 7.2.1 Europe Viscosupplementation Market by Application
- 7.2.1.1 Europe Knee Osteoarthritis Market by Country
- 7.2.1.2 Europe Hand Osteoarthritis Market by Country
- 7.2.1.3 Europe Hip Osteoarthritis Market by Country
- 7.2.1.4 Europe Others Market by Country
- 7.2.2 Europe Viscosupplementation Market by Product
- 7.2.2.1 Europe Three Injection Market by Country
- 7.2.2.2 Europe Single Injection Market by Country
- 7.2.2.3 Europe Five Injection Market by Country
- 7.2.3 Europe Viscosupplementation Market by End-use
- 7.2.3.1 Europe Hospitals Market by Country
- 7.2.3.2 Europe Orthopedic Clinics/ASCs Market by Country
- 7.2.4 Europe Viscosupplementation Market by Country
- 7.2.4.1 Germany Viscosupplementation Market
- 7.2.4.1.1 Germany Viscosupplementation Market by Application
- 7.2.4.1.2 Germany Viscosupplementation Market by Product
- 7.2.4.1.3 Germany Viscosupplementation Market by End-use
- 7.2.4.2 UK Viscosupplementation Market
- 7.2.4.2.1 UK Viscosupplementation Market by Application
- 7.2.4.2.2 UK Viscosupplementation Market by Product
- 7.2.4.2.3 UK Viscosupplementation Market by End-use
- 7.2.4.3 France Viscosupplementation Market
- 7.2.4.3.1 France Viscosupplementation Market by Application
- 7.2.4.3.2 France Viscosupplementation Market by Product
- 7.2.4.3.3 France Viscosupplementation Market by End-use
- 7.2.4.4 Russia Viscosupplementation Market
- 7.2.4.4.1 Russia Viscosupplementation Market by Application
- 7.2.4.4.2 Russia Viscosupplementation Market by Product
- 7.2.4.4.3 Russia Viscosupplementation Market by End-use
- 7.2.4.5 Spain Viscosupplementation Market
- 7.2.4.5.1 Spain Viscosupplementation Market by Application
- 7.2.4.5.2 Spain Viscosupplementation Market by Product
- 7.2.4.5.3 Spain Viscosupplementation Market by End-use
- 7.2.4.6 Italy Viscosupplementation Market
- 7.2.4.6.1 Italy Viscosupplementation Market by Application
- 7.2.4.6.2 Italy Viscosupplementation Market by Product
- 7.2.4.6.3 Italy Viscosupplementation Market by End-use
- 7.2.4.7 Rest of Europe Viscosupplementation Market
- 7.2.4.7.1 Rest of Europe Viscosupplementation Market by Application
- 7.2.4.7.2 Rest of Europe Viscosupplementation Market by Product
- 7.2.4.7.3 Rest of Europe Viscosupplementation Market by End-use
- 7.3 Asia Pacific Viscosupplementation Market
- 7.3.1 Asia Pacific Viscosupplementation Market by Application
- 7.3.1.1 Asia Pacific Knee Osteoarthritis Market by Country
- 7.3.1.2 Asia Pacific Hand Osteoarthritis Market by Country
- 7.3.1.3 Asia Pacific Hip Osteoarthritis Market by Country
- 7.3.1.4 Asia Pacific Others Market by Country
- 7.3.2 Asia Pacific Viscosupplementation Market by Product
- 7.3.2.1 Asia Pacific Three Injection Market by Country
- 7.3.2.2 Asia Pacific Single Injection Market by Country
- 7.3.2.3 Asia Pacific Five Injection Market by Country
- 7.3.3 Asia Pacific Viscosupplementation Market by End-use
- 7.3.3.1 Asia Pacific Hospitals Market by Country
- 7.3.3.2 Asia Pacific Orthopedic Clinics/ASCs Market by Country
- 7.3.4 Asia Pacific Viscosupplementation Market by Country
- 7.3.4.1 China Viscosupplementation Market
- 7.3.4.1.1 China Viscosupplementation Market by Application
- 7.3.4.1.2 China Viscosupplementation Market by Product
- 7.3.4.1.3 China Viscosupplementation Market by End-use
- 7.3.4.2 Japan Viscosupplementation Market
- 7.3.4.2.1 Japan Viscosupplementation Market by Application
- 7.3.4.2.2 Japan Viscosupplementation Market by Product
- 7.3.4.2.3 Japan Viscosupplementation Market by End-use
- 7.3.4.3 India Viscosupplementation Market
- 7.3.4.3.1 India Viscosupplementation Market by Application
- 7.3.4.3.2 India Viscosupplementation Market by Product
- 7.3.4.3.3 India Viscosupplementation Market by End-use
- 7.3.4.4 South Korea Viscosupplementation Market
- 7.3.4.4.1 South Korea Viscosupplementation Market by Application
- 7.3.4.4.2 South Korea Viscosupplementation Market by Product
- 7.3.4.4.3 South Korea Viscosupplementation Market by End-use
- 7.3.4.5 Singapore Viscosupplementation Market
- 7.3.4.5.1 Singapore Viscosupplementation Market by Application
- 7.3.4.5.2 Singapore Viscosupplementation Market by Product
- 7.3.4.5.3 Singapore Viscosupplementation Market by End-use
- 7.3.4.6 Malaysia Viscosupplementation Market
- 7.3.4.6.1 Malaysia Viscosupplementation Market by Application
- 7.3.4.6.2 Malaysia Viscosupplementation Market by Product
- 7.3.4.6.3 Malaysia Viscosupplementation Market by End-use
- 7.3.4.7 Rest of Asia Pacific Viscosupplementation Market
- 7.3.4.7.1 Rest of Asia Pacific Viscosupplementation Market by Application
- 7.3.4.7.2 Rest of Asia Pacific Viscosupplementation Market by Product
- 7.3.4.7.3 Rest of Asia Pacific Viscosupplementation Market by End-use
- 7.4 LAMEA Viscosupplementation Market
- 7.4.1 LAMEA Viscosupplementation Market by Application
- 7.4.1.1 LAMEA Knee Osteoarthritis Market by Country
- 7.4.1.2 LAMEA Hand Osteoarthritis Market by Country
- 7.4.1.3 LAMEA Hip Osteoarthritis Market by Country
- 7.4.1.4 LAMEA Others Market by Country
- 7.4.2 LAMEA Viscosupplementation Market by Product
- 7.4.2.1 LAMEA Three Injection Market by Country
- 7.4.2.2 LAMEA Single Injection Market by Country
- 7.4.2.3 LAMEA Five Injection Market by Country
- 7.4.3 LAMEA Viscosupplementation Market by End-use
- 7.4.3.1 LAMEA Hospitals Market by Country
- 7.4.3.2 LAMEA Orthopedic Clinics/ASCs Market by Country
- 7.4.4 LAMEA Viscosupplementation Market by Country
- 7.4.4.1 Brazil Viscosupplementation Market
- 7.4.4.1.1 Brazil Viscosupplementation Market by Application
- 7.4.4.1.2 Brazil Viscosupplementation Market by Product
- 7.4.4.1.3 Brazil Viscosupplementation Market by End-use
- 7.4.4.2 Argentina Viscosupplementation Market
- 7.4.4.2.1 Argentina Viscosupplementation Market by Application
- 7.4.4.2.2 Argentina Viscosupplementation Market by Product
- 7.4.4.2.3 Argentina Viscosupplementation Market by End-use
- 7.4.4.3 UAE Viscosupplementation Market
- 7.4.4.3.1 UAE Viscosupplementation Market by Application
- 7.4.4.3.2 UAE Viscosupplementation Market by Product
- 7.4.4.3.3 UAE Viscosupplementation Market by End-use
- 7.4.4.4 Saudi Arabia Viscosupplementation Market
- 7.4.4.4.1 Saudi Arabia Viscosupplementation Market by Application
- 7.4.4.4.2 Saudi Arabia Viscosupplementation Market by Product
- 7.4.4.4.3 Saudi Arabia Viscosupplementation Market by End-use
- 7.4.4.5 South Africa Viscosupplementation Market
- 7.4.4.5.1 South Africa Viscosupplementation Market by Application
- 7.4.4.5.2 South Africa Viscosupplementation Market by Product
- 7.4.4.5.3 South Africa Viscosupplementation Market by End-use
- 7.4.4.6 Nigeria Viscosupplementation Market
- 7.4.4.6.1 Nigeria Viscosupplementation Market by Application
- 7.4.4.6.2 Nigeria Viscosupplementation Market by Product
- 7.4.4.6.3 Nigeria Viscosupplementation Market by End-use
- 7.4.4.7 Rest of LAMEA Viscosupplementation Market
- 7.4.4.7.1 Rest of LAMEA Viscosupplementation Market by Application
- 7.4.4.7.2 Rest of LAMEA Viscosupplementation Market by Product
- 7.4.4.7.3 Rest of LAMEA Viscosupplementation Market by End-use
Chapter 8. Company Profiles
- 8.1 DePuy Synthes (Johnson & Johnson)
- 8.1.1 Company Overview
- 8.1.2 Financial Analysis
- 8.1.3 Segmental & Regional Analysis
- 8.1.4 Research & Development Expenses
- 8.1.5 SWOT Analysis
- 8.2 Sanofi S.A.
- 8.2.1 Company Overview
- 8.2.2 Financial Analysis
- 8.2.3 Segmental and Regional Analysis
- 8.2.4 Research & Development Expense
- 8.2.5 SWOT Analysis
- 8.3 Zimmer Biomet Holdings, Inc.
- 8.3.1 Company Overview
- 8.3.2 Financial Analysis
- 8.3.3 Regional Analysis
- 8.3.4 Research & Development Expense
- 8.3.5 SWOT Analysis
- 8.4 Ferring Holdings SA
- 8.4.1 Company Overview
- 8.4.2 Financial Analysis
- 8.4.3 Regional Analysis
- 8.4.4 Research and Development Expense
- 8.4.5 SWOT Analysis
- 8.5 F. Hoffmann-La Roche Ltd.
- 8.5.1 Company Overview
- 8.5.2 Financial Analysis
- 8.5.3 Segmental and Regional Analysis
- 8.5.4 Research & Development Expense
- 8.5.5 SWOT Analysis
- 8.6 LG Chem Ltd. (LG Corporation)
- 8.6.1 Company Overview
- 8.6.2 Financial Analysis
- 8.6.3 Segmental and Regional Analysis
- 8.6.4 SWOT Analysis
- 8.7 Anika Therapeutics, Inc.
- 8.7.1 Company Overview
- 8.7.2 Financial Analysis
- 8.7.3 Regional Analysis
- 8.7.4 Research & Development Expenses
- 8.7.5 SWOT Analysis
- 8.8 Fidia Farmaceutici S.p.A. (P&R Farmaceutici S.p.A)
- 8.8.1 Company Overview
- 8.8.2 Financial Analysis
- 8.8.3 Regional Analysis
- 8.8.4 Research & Development Expenses
- 8.8.5 SWOT Analysis
- 8.9 Smith & Nephew PLC
- 8.9.1 Company Overview
- 8.9.2 Financial Analysis
- 8.9.3 Regional and Segmental Analysis
- 8.9.4 Research & Development Expense
- 8.9.5 SWOT Analysis
- 8.10. Seikagaku Corp.
- 8.10.1 Company Overview
- 8.10.2 Financial Analysis
- 8.10.3 Segmental Analysis
- 8.10.4 Research & Development Expenses
- 8.10.5 SWOT Analysis
Chapter 9. Winning Imperative for Viscosupplementation Market